Secondary analysis of a trial in 101 adults with CKD and overweight or obesity without type 2 diabetes: 24 weeks of semaglutide vs placebo reduced weight by 9.1 kg, but lean and fat mass changes did not correlate with eGFR or measured GFR changes.
Secondary analysisn = 101
Heerspink et al. Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial